Source-grounded facts extracted from Kezar Life Sciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kezar Life Sciences, Inc.: Bylaws amended and restated entirely pursuant to merger agreement.
“the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, as set forth on Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.”
Kezar Life Sciences, Inc.: Certificate of incorporation amended and restated entirely pursuant to merger agreement.
“the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, as set forth on Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.”
Kezar Life Sciences, Inc. underwent a change of control involving Aurinia Pharma U.S., Inc. for $6.955 per Share, payable in cash, without interest, plus one contingent value right per Share (closed 2026-05-11).
“11, 2026, Parent completed a tender offer to purchase all of the Company’s outstanding shares (the “ Shares ”) of common stock, par value $0.001 per share, in exchange for (i) $6.955 per Share, payable in cash, without interest (such amount, or any different amount per Share paid pursuant to the Offer, the “ Cash Amount ”), plus (ii) one contingent value”
Stephen Robertson was appointed as Chief Legal Officer, Corporate Secretary and Chief Compliance Officer at Kezar Life Sciences, Inc..
“The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.”
Michael Hearne was appointed as Chief Financial Officer at Kezar Life Sciences, Inc..
“The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.”
Ryan Cole was appointed as Chief Operating Officer at Kezar Life Sciences, Inc..
“The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.”
Kevin Tang was appointed as Chief Executive Officer at Kezar Life Sciences, Inc..
“The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, Chief Executive Officer, Ryan Cole, Chief Operating Officer, Michael Hearne, Chief Financial Officer, and Stephen Robertson, Chief Legal Officer, Corporate Secretary and Chief Compliance Officer.”
Kevin Tang was appointed as Sole Director at Kezar Life Sciences, Inc..
“the sole director and officers of Merger Sub immediately prior to the Effective Time became the sole director and officers of the Surviving Corporation. The sole director of Merger Sub immediately prior to the Effective Time was Kevin Tang.”
Mark Schiller departed as Officer at Kezar Life Sciences, Inc..
“Christopher J. Kirk, Ph.D., Marc L. Belsky and Mark Schiller entered into separation agreements with the Company. Each officer’s employment with the Company will terminate at the Effective Time.”
Marc L. Belsky departed as Officer at Kezar Life Sciences, Inc..
“Christopher J. Kirk, Ph.D., Marc L. Belsky and Mark Schiller entered into separation agreements with the Company. Each officer’s employment with the Company will terminate at the Effective Time.”
Christopher J. Kirk departed as Officer at Kezar Life Sciences, Inc..
“Christopher J. Kirk, Ph.D., Marc L. Belsky and Mark Schiller entered into separation agreements with the Company. Each officer’s employment with the Company will terminate at the Effective Time.”
Courtney Wallace resigned as Director at Kezar Life Sciences, Inc..
“at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.”
Micki Klearman resigned as Director at Kezar Life Sciences, Inc..
“at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.”
Michael Kauffman resigned as Director at Kezar Life Sciences, Inc..
“at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.”
Elizabeth Garner resigned as Director at Kezar Life Sciences, Inc..
“at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.”
Graham Cooper resigned as Director at Kezar Life Sciences, Inc..
“at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.”
Franklin Berger resigned as Director at Kezar Life Sciences, Inc..
“at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.”
John Fowler resigned as Director at Kezar Life Sciences, Inc..
“at the Effective Time, each of John Fowler, Franklin Berger, Graham Cooper, Elizabeth Garner, M.D., Michael Kauffman, M.D., Ph.D., Micki Klearman, M.D. and Courtney Wallace resigned from the board of directors of the Company.”
Kezar Life Sciences, Inc. terminated Lease Termination Agreement with GNS South Tower, LP valued at $2 million (effective 2026-04-01).
“On April 1, 2026, Kezar Life Sciences, Inc. (the “Company”) entered into a lease termination agreement (the “Lease Termination Agreement”) with GNS South Tower, LP (the “Landlord”) to terminate that certain lease agreement, dated as of August 16, 2017, as amended (the “Lease”), for approximately 48,714 rentable square feet at 4000 Shoreline Court, San Francisco, California.”
Kezar Life Sciences, Inc. entered into Agreement and Plan of Merger with Aurinia Pharma U.S., Inc. valued at $6.955 per Share (effective 2026-03-30).
“On March 30, 2026, Kezar Life Sciences, Inc., a Delaware corporation (the “ Company ” or “ Kezar ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Aurinia Pharma U.S., Inc., a Delaware corporation (“ Parent ” or “Aurinia”), Aurinia Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ” and together with Parent, the “ Buyer Entities ”), and, solely for purposes of Section 10.13 of the Merger Agreement, Aurinia Pharmaceuticals Inc., a company incorporated under the laws of the Province of Alberta (“ Ultimate Parent ”), and the parent entity of Parent.”
Kezar Life Sciences, Inc. entered into Asset Purchase Agreement with Enodia Therapeutics SAS valued at $800,000 in cash at the closing and will receive an additional $200,000 on the earlier to occur of ( (effective 2026-03-06).
“On March 6, 2026, Kezar Life Sciences, Inc. (the “Company”) and Enodia Therapeutics SAS, a French simplified joint stock company (“Enodia”), entered into an asset purchase agreement (the “Agreement”) pursuant to which Enodia (i) acquired all of the Company’s rights, title and interest in the Company’s Sec61-based discovery and development program assets, including the product candidate internally known as KZR-261 (collectively, the “Assets”); and (ii) assumed liabilities from the Company related to certain transferred contracts and from the ownership, use, operation or maintenance of the Assets under the Agreement (the “Transaction”).”
Kezar Life Sciences, Inc. completed a disposition involving Enodia Therapeutics SAS for $800,000 in cash at the closing (closed 2026-03-06).
“assets related to the Company’s zetomizomib program, employee contracts, cash, accounts receivable, real property or equipment. Pursuant to the Agreement, the Company received $800,000 in cash at the closing and will receive an additional $200,000 on the earlier to occur of (i) physical delivery of certain inventory assets to Enodia and (ii) 45 days after the”
Kezar Life Sciences, Inc. announced a restructuring with charges of approximately $6.0 million affecting the Company (approximately 31 employees, or approximately 70%).
“restructuring plan in connection with its previously announced evaluation of strategic alternatives. The Company estimates that it will incur cash expenditures of approximately $6.0 million, consisting primarily of one-time severance payments, benefits and other related costs. The Company expects to recognize the majority of such costs in the fourth quarter of 2025.”
Kezar Life Sciences, Inc. issued securities.
“On October 16, 2025, the Company entered into Amendment No. 2 (the “Amendment”) to the Rights Agreement, dated as of October 17, 2024, as amended on December 3, 2024, by and between the Company and Computershare Trust Company, N.A., as rights agent (as amended, the “Rights Agreement”).”
Pichi (Pattie) Chiang was appointed as principal accounting officer at Kezar Life Sciences, Inc..
“On March 27, 2025, Kezar Life Sciences, Inc. (the “Company”) appointed Pichi (Pattie) Chiang as the Company's principal accounting officer, effective April 1, 2025.”
Kezar Life Sciences, Inc.: Amended certificate of incorporation to effect a 1-for-10 reverse stock split (effective 2024-10-29).
“On October 28, 2024, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment of its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to effect the Reverse Stock Split. The Charter Amendment will become effective at 5:00 p.m. Eastern Time on October 29, 2024 (the “Effective Time”).”
Kezar Life Sciences, Inc.: Board approved Certificate of Designations establishing Preferred Shares; filed with Delaware Secretary of State on October 17, 2024 (effective 2024-10-17).
“the Board approved the Certificate of Designations establishing the Preferred Shares and the rights, preferences and privileges thereof. The Certificate of Designations was filed with the Secretary of State of the State of Delaware on October 17, 2024.”
Kezar Life Sciences, Inc. reported first quarter ended March 31, 2024 results: net income $21.7 million, EPS $0.30 per basic and diluted common share.
“Net loss for the first quarter of 2024 was $21.7 million, or $0.30 per basic and diluted common share”
Kezar Life Sciences, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $7.0 million.
“Revenue for the year of 2023 was $7.0 million resulting from the upfront payment under the collaboration and license agreement with Everest Medicines.”
Kezar Life Sciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“December 1, 2023, Kezar Life Sciences, Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Stock Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the C”
Kezar Life Sciences, Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 13, 2023, Kezar Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.”
Noreen Roth Henig departed as Chief Medical Officer at Kezar Life Sciences, Inc..
“On September 30, 2023, as previously announced, the board of directors of Kezar Life Sciences, Inc. (the “Company”) and Noreen Roth Henig, M.D., the Company’s former Chief Medical Officer, reached the mutual decision for Dr. Henig to step down as Chief Medical Officer effective October 6, 2023.”
Kezar Life Sciences, Inc. announced a impairment affecting research and drug discovery activities.
“The Company may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the workforce reduction, including potential impairment charges due to the pausing of the Company’s research and drug discovery activities. However, the Company is not able to estimate the amount or range of amounts of such potential impairments as of the date of this Current Report on Form 8-K.”
Kezar Life Sciences, Inc. announced a restructuring with charges of approximately $2.9 million to $3.2 million (approximately 41%).
“will pause all research and drug discovery activities. The Company anticipates the one-time severance-related charge associated with the workforce reduction to be approximately $2.9 million to $3.2 million. The severance-related charge, which is expected to represent cash expenditures that the Company expects to incur in connection with the workforce reduction, are”
Christopher Kirk was appointed as Chief Executive Officer at Kezar Life Sciences, Inc..
“Christopher Kirk, Ph.D., the Company’s co-founder and member of the Board, has been appointed to serve as Chief Executive Officer, effective as of the Effective Date.”
John Fowler resigned as Chief Executive Officer at Kezar Life Sciences, Inc..
“On September 30, 2023, John Fowler, the Company’s co-founder, Chief Executive Officer and member of the Board, notified the Board that he will resign and cease serving as Chief Executive Officer, effective November 7, 2023”
Kezar Life Sciences, Inc. entered into Collaboration and License Agreement with Everest Medicines II (HK) Limited valued at initial upfront payment of $7.0 million; potential milestone payments of up to $125.5 million; tiere (effective 2023-09-20).
“On September 20, 2023, Kezar Life Sciences, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “License Agreement”) with Everest Medicines II (HK) Limited (“Everest”) pursuant to which, among other things, the Company granted to Everest an exclusive license to develop and commercialize one or more products containing the Company’s proprietary compound, zetomipzomib (collectively, the “Products”), in the licensed field in the greater China region (mainland China, Taiwan, Hong Kong and Macau), South Korea, Singapore, Malaysia, Thailand, Indonesia, Vietnam and the Philippines (the “Territory”).”
Kezar Life Sciences, Inc. reported financial results for the second quarter ended June 30, 2023.
“On August 10, 2023, Kezar Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.”
Kezar Life Sciences, Inc.: Increased authorized shares from 135,000,000 to 260,000,000, consisting of 250,000,000 common and 10,000,000 preferred shares (effective 2023-06-14).
“On June 14, 2023, following receipt of the affirmative vote from the holders of a majority of the outstanding shares of common stock of Kezar Life Sciences, Inc. (the “Company”) at its 2023 annual meeting of stockholders (the “Annual Meeting”), the Company filed a certificate of amendment to the Company’s amended and restated certificate of incorporation (the “Certificate Amendment”) with the Secretary of State of the State of Delaware to increase the authorized number of total shares of all classes of stock that the Company has authority to issue from 135,000,000 shares to 260,000,000 shares, consisting of two classes: (1) 250,000,000 shares of common stock, $0.0001 par value per share, and (2) 10,000,000 shares of preferred stock, $0.001 par value per share. The Certificate Amendment became effective immediately upon filing.”
Kezar Life Sciences, Inc. shareholders approved Approval of amendment to amended and restated certificate of incorporation to increase number of authorized shares of common stock at the 2023-06-14 meeting.
“Proposal 3 : The Company’s stockholders approved an amendment to the Company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock by the votes set forth in the table below: Votes For Votes Against Abstain 65,253,861 890,792 94,735”
Kezar Life Sciences, Inc. shareholders approved Ratification of selection of KPMG LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-14 meeting.
“Proposal 2 : The Company’s stockholders ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the votes set forth in the table below: Votes For Votes Against Abstain 66,231,058 5,202 3,128”
Kezar Life Sciences, Inc. shareholders approved Election of three Class II directors at the 2023-06-14 meeting.
“On June 14, 2023, the Company held its Annual Meeting. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2023. Proposal 1 : The Company’s stockholders elected the three nominees of the Company’s board of directors to serve as Class II directors until the 2026 annual meeting of stockholders, or until their successors are duly elected and qualified, by the votes set forth in the table below: Nominee Votes For Votes Withheld Broker Non-Votes Franklin Berger 33,265,209 22,578,381 10,395,798 Graham Cooper 55,391,603 451,987 10,395,798 Micki Klearman, M.D. 51,104,468 4,739,122 10,395,798”
Kezar Life Sciences, Inc. reported financial results for the first quarter ended March 31, 2023.
“Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.”
Christopher Kirk resigned as President and Chief Scientific Officer at Kezar Life Sciences, Inc..
“On April 21, 2023, as previously announced, Christopher Kirk, Ph.D. resigned from his role as President and Chief Scientific Officer of Kezar Life Sciences, Inc. (the “Company”).”
Christopher Kirk resigned as President and Chief Scientific Officer at Kezar Life Sciences, Inc..
“On February 27, 2023, Christopher Kirk, Ph.D., President, Chief Scientific Officer and member of the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”), provided notice of his intention to resign from the positions of President and Chief Scientific Officer of the Company for personal reasons, effective April 21, 2023 (the “Resignation Date”).”
Kezar Life Sciences, Inc. reported financial results for the third quarter ended September 30, 2022.
“Kezar Life Sciences Reports Third Quarter 2022 Financial Results”
Graham Cooper was appointed as Chairman of the Board at Kezar Life Sciences, Inc..
“the Board appointed current director Graham Cooper as Chairman of the Board”
Jean-Pierre Sommadossi resigned as Chairman of the Board of Directors at Kezar Life Sciences, Inc..
“On May 11, 2022, Jean-Pierre Sommadossi, Ph.D., Chairman of the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”) tendered his resignation from the Board effective immediately.”
Courtney Wallace was appointed as Director at Kezar Life Sciences, Inc..
“Effective December 9, 2021, the Board appointed Courtney Wallace to the Board as a Class I Director, to serve until the Company’s 2022 annual meeting of stockholders and until her successor is duly elected and qualified, or her earlier resignation or removal.”
Jason Dinges resigned as Director at Kezar Life Sciences, Inc..
“Effective December 9, 2021, Jason Dinges, Ph.D., resigned from the Board of Directors (the “Board”) of Kezar Life Sciences, Inc. (the “Company”) and from his position as a member of the Nominating and Corporate Governance Committee of the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.